Ocugen’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Ocugen is a clinical stage biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of ocular disorders. Read more

Shankar Musunuri's photo - Chairman & CEO of Ocugen

Chairman & CEO

Shankar Musunuri

CEO Approval Rating

88/100

Founded:

2013

Status:

PublicNASDAQOCGN

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Aerpio is seen as one of Ocugen's top competitors. Aerpio is headquartered in Cincinnati, Ohio, and was founded in 2011. Aerpio is in the Pharmaceuticals field. Aerpio generates 70,389% the revenue of Ocugen.

ONL Therapeutics has been one of Ocugen's top competitors. ONL Therapeutics's headquarters is in Ann Arbor, Michigan, and was founded in 2006. Like Ocugen, ONL Therapeutics also operates in the Biotechnology field. ONL Therapeutics generates 8,740% of Ocugen's revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Kodiak Sciences a competitor of Ocugen?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$ < 1M

Ocugen's revenue is the ranked 14th among it's top 10 competitors. The top 10 competitors average 1.1B. Over the last one quarters, Ocugen's revenue has decreased by 0%. Specifically, in Q2 2020's revenue was $ < 1M.

Acquisitions

No recent acquisitions found related to Ocugen

Ocugen Funding History

$6.2M$13.7M$19.1M$44.1M$44.8M

Since Ocugen was founded in 2013, it has participated in 8 rounds of funding. In total Ocugen has raised $44.8M. Ocugen's last funding round was on Apr 2020 for a total of $421.4K

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt - PPP (CARES Act)
Apr 2020
$421.4K
Debt - PPP (CARES Act)
Apr 2020
$350K - $1M

U.S. Small Business Administration.

Private Placement
Sep 2019
$25M
-
Equity
Nov 2018
$350.4K
-
Equity
Jan 2018
$5M
-

Total Funding: $44.8M

Since Ocugen was founded in 2013, it has participated in 8 rounds of funding. In total Ocugen has raised $44.8M. Ocugen's last funding round was on Apr 2020 for a total of $421.4K

Investments

No recent investments found related to Ocugen

Ocugen News

August 14, 2020NewsOk

2Q Earnings Snapshot

August 11, 2020MarketScreener

Corporate Deck

(marketscreener.com) sets clear path for critical manufacturing OCU200: Targeting major retinal disea... See more »
August 11, 2020The Business Journals: Philadelphia

Malvern gene therapy company nabs fourth orphan drug designation for a single product

The company has now received four orphan drug designations for a single product targeting inherited e... See more »
July 21, 2020Benzinga

Ocugen to Present at World Orphan Drug Congress USA 2020 Conference

MALVERN, Pa., July 21, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a biopharmaceutical compa... See more »
June 2, 2020The Business Journals: Philadelphia

Malvern life sciences company halts late-stage study of new drug candidate

Ocugen, a Chester County gene therapy developer focusing on eye disorders, has discontinued late-stag... See more »

Ocugen Press Releases

April 22, 2020centralcharts

Ocugen Announces Completion of Warrant Exchange

MALVERN, Pa., April 22, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage compan... See more »
March 18, 2020Network Newswire

OCGN) Featured in Virtual Coverage of the 32nd Annual ROTH Conference - NetworkNewsWire

Ocugen, Inc. (NASDAQ: OCGN) is a clinical-stage biopharmaceutical company focused on discovering, dev... See more »
February 16, 2020Network Newswire

OCGN) Starts Presentation at NobleCon16 - NetworkNewsWire

Ocugen (NASDAQ: OCGN) is a clinical-stage biopharmaceutical company focused on discovering, developin... See more »
April 23, 2018PR Newswire

Ocugen Announces CEO Dr. Shankar Musunuri Named a Finalist for Ernst & Young Entrepreneur Of The Year® 2018 Award

MALVERN, Pa., April 23, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company de... See more »
March 15, 2018PR Newswire

Ocugen to Present at the Oppenheimer 28th Annual Healthcare Conference

MALVERN, Pa., March 15, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company de... See more »
February 6, 2018PR Newswire

Ocugen to Present at 2018 BIO CEO & Investor Conference

MALVERN, Pa., Feb. 6, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company deve... See more »
August 28, 2017Blackbird

Ocugen Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017

MALVERN, Pa., Aug. 28, 2017 /PRNewswire/ -- Ocugen, Inc. today announced it will be featured as a pre... See more »

Headquarters

5 Great Valley Parkway Suite 160

Malvern, Pennsylvania19355

484-328-4701

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Ocugen is a clinical stage biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of ocular disorders. Ocugen was founded in 2013. Ocugen's headquarters is located in Malvern, Pennsylvania, USA 19355. It has ...

CEO

Ocugen's Chairman & CEO, Shankar Musunuri, currently has an approval rating of 88%. Ocugen's primary competitors are Graybug Vision, Aerpio & ONL Therapeutics.

Website

ocugen.com

Frequently Asked Questions about Ocugen

  1. When was Ocugen founded?

    Ocugen was founded in 2013
  2. Who is Ocugen's CEO?

    Ocugen's CEO is Shankar Musunuri
  3. How much revenue does Ocugen generate?

    Ocugen generates $ < 1M in revenue
  4. How much funding does Ocugen have?

    Ocugen has historically raised $44.8M in funding
  1. Where is Ocugen's headquarters?

    Ocugen's headquarters is in Malvern Pennsylvania, USA
  2. How many employees does Ocugen have?

    Ocugen has 49 employees
  3. What sector does Ocugen operate in?

    Ocugen is in Biotechnology
  4. Who are Ocugen's competitors?

    Ocugen's top competitors are Graybug Vision, Aerpio, ONL Therapeutics